Does Otrexup Cause Lung Problems?
Otrexup (methotrexate injection) carries risks of serious lung issues, primarily methotrexate-induced pneumonitis, a potentially fatal inflammation of the lung tissue. This occurs in 0.3% to 18% of patients, depending on dose and duration, with higher rates in rheumatoid arthritis treatment. Symptoms include dry cough, shortness of breath, fever, and chest pain, often appearing acutely within weeks to months of starting therapy.[1][2]
How Common Is Methotrexate Lung Toxicity?
Pneumonitis risk is dose-dependent: low weekly doses (under 15 mg) for rheumatoid arthritis pose lower risk (around 1-5%), while higher doses for cancer elevate it to 10-18%. Pre-existing lung disease, older age, diabetes, and hypoalbuminemia increase susceptibility. Hypersensitivity pneumonitis is the main mechanism, involving immune-mediated damage rather than direct toxicity.[1][3]
What Are the Warning Signs and When Do They Appear?
Watch for progressive dyspnea, non-productive cough, fever, and crackles on lung exam. Symptoms typically emerge 1-8 weeks after initiation but can occur anytime, even after years. Chest X-ray or CT shows interstitial infiltrates; pulmonary function tests reveal restrictive patterns and reduced diffusion capacity.[2][4]
How Serious Can It Get, and What's the Treatment?
Untreated, it progresses to respiratory failure and death in up to 30% of cases. Discontinue methotrexate immediately upon suspicion; most recover with corticosteroids (e.g., prednisone 1 mg/kg/day), though some need oxygen or ventilation. Re-challenge is contraindicated due to 30-50% recurrence risk.[1][3]
Who’s at Higher Risk and How to Prevent It?
Patients with rheumatoid arthritis on concurrent DMARDs (e.g., leflunomide) or those with rheumatoid lung disease face amplified risks. Baseline pulmonary function tests and chest imaging are recommended for at-risk patients. Monitor closely during first months; avoid in active interstitial lung disease.[2][4]
Can It Be Reversed or Does It Cause Permanent Damage?
About 80-90% recover fully with prompt treatment, but 10-20% develop fibrosis or chronic issues. Early diagnosis via BAL (showing lymphocytosis) or biopsy (confirming non-infectious pneumonitis) is key. No specific antidote exists.[3]
Sources:
[1] [Otrexup FDA Label]
[2] [UpToDate: Methotrexate Pneumonitis]
[3] [NEJM Review on Methotrexate Lung Toxicity]
[4] [ACR Guidelines Excerpt]